The first panel at the inaugural Edison Growth Conference 2024 explored disruptive technology and AI. AI is certainly the fastest and possibly one of the most significant technology transition cycles of the 21st century. We have already seen significant value created but, with the proposed takeover of Dark Trace, UK markets are currently underexposed. This is despite the fact that the UK is one of the global leaders in the space, ranking third across a number of metrics behind the US and China. The UK investment community needs to find the appetite, expertise and structures to support innovative AI businesses through the scale-up phase and benefit from the significant value which could be created. To do this, attitudes to growth and risks need to be reassessed. Watch the recording of the discussion moderated by Edison’s Dani Ridsdale and featuring: • Ali Mortazavi, CEO, e-therapeutics (LSE:ETX) • Cyrus Mewawalla, head of thematic intelligence, GlobalData (LSE:AIM) • Ami Daniel, co-founder and CEO, Windward (LSE:WNWD) • Ben Wilkinson, CFO, Molten Ventures (LSE:GROW)

e-therapeutics is a UK biotech company using proprietary computational biology and RNAi platforms to discover novel disease targets and therapies. The company is specifically focused on leveraging its expertise to design treatments for hepatocyte-associated disease indications (not restricted to diseases in the liver) with untapped, novel targets, providing scope for new treatments to have a unique offering. In partnership with Curation Connect, we are pleased to share the e-therapeutics showcase, which curates a range of different Edison, company and industry material for investors to learn more about this stock.